These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9893221)

  • 1. [Trends of prostate cancer: comparison between 1986-90 and 1991-95 at Asahi General Hospital].
    Tanaka M; Murakami S; Suzuki N; Oikawa T; Kinsui H; Hamano S; Shimazaki J
    Hinyokika Kiyo; 1998 Nov; 44(11):775-80. PubMed ID: 9893221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asian trends in prostate cancer hormone therapy.
    Akaza H; Naito S; Cheng C; Kaisary A; Soebadi DM; Umbas R; Esuvaranathan K; Gu FL; Zhou L; Hong SJ; Kim WJ; Lee SE; Rim JS; Song JM; Yoon JH; Chang SJ; Huang CH; Yang CR; Hirao Y; Murai M; Tsukamoto T; Usami M
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1951-61. PubMed ID: 12465395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical studies on endocrine therapy of prostatic carcinoma (2): Prognosis of patients with prostatic carcinoma given endocrine therapy, and analyses of causes of death and side effects of endocrine therapy].
    Kumamoto Y; Tsukamoto T; Umehara T; Shimazaki J; Fuse H; Oshima H; Takeuchi H; Yoshida O; Okada K; Saito Y
    Hinyokika Kiyo; 1990 Mar; 36(3):285-93. PubMed ID: 2191570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance.
    Akaza H; Usami M; Hinotsu S; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Hirao Y; Murai M; Yamanaka H
    Jpn J Clin Oncol; 2004 Jun; 34(6):329-36. PubMed ID: 15333685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D conformal radiation therapy for prostate cancer in elderly patients.
    Geinitz H; Zimmermann FB; Thamm R; Schumertl A; Busch R; Molls M
    Radiother Oncol; 2005 Jul; 76(1):27-34. PubMed ID: 15990188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors of prostate cancer treated with first-line hormone therapy].
    Rigaud J; Le Normand L; Karam G; Glemain P; Buzelin JM; Bouchot O
    Prog Urol; 2002 Apr; 12(2):232-9. PubMed ID: 12108337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
    Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
    Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical studies on 179 cases of prostatic cancer].
    Uchida T; Honda N; Yokota S; Ao T; Ikeda S; Odajima K; Mashimo S; Endo T; Ishibashi A; Koshiba K
    Hinyokika Kiyo; 1987 Jun; 33(6):869-76. PubMed ID: 3673838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of prostate cancer: statistical analysis of 107 cases in the past 12 years].
    Umeda Y; Hayashi N; Ogawa K; Kuromatsu I; Franco OE; Su J; Yamakawa K; Arima K; Yanagawa M; Kawamura J
    Hinyokika Kiyo; 2000 Dec; 46(12):873-8. PubMed ID: 11211803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer.
    Homma Y; Akaza H; Okada K; Yokoyama M; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 Apr; 11(4):218-24. PubMed ID: 15028100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent trends of gallbladder cancer in Japan: an analysis of 4,770 patients.
    Kayahara M; Nagakawa T
    Cancer; 2007 Aug; 110(3):572-80. PubMed ID: 17594719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.